{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:53:11Z","timestamp":1777679591895,"version":"3.51.4"},"reference-count":20,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,3,22]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>This report describes a woman in her early 70s who developed severe central adrenal insufficiency 11 months after completing 1 year of adjuvant pembrolizumab for resected clear cell renal cell carcinoma. She presented with debilitating fatigue, profound weakness, unintentional weight loss and hypotension. Because these symptoms were non-specific and emerged long after immunotherapy discontinuation, the diagnosis was delayed for several months. Laboratory testing showed a markedly suppressed morning cortisol with an inappropriately low adrenocorticotropic hormone (ACTH) level and no response to cosyntropin, confirming central adrenal insufficiency. Other pituitary hormone axes remained intact, consistent with isolated ACTH deficiency. Imaging demonstrated adrenal atrophy, supporting chronic central adrenal insufficiency. The patient improved rapidly after starting hydrocortisone replacement. This case highlights a prolonged interval between checkpoint inhibitor cessation and endocrine toxicity, emphasising the importance of continued surveillance for late-onset immune-related endocrinopathies even after therapy completion.<\/jats:p>","DOI":"10.1136\/bcr-2025-271276","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:55:22Z","timestamp":1776178522000},"page":"e271276","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Delayed-onset central adrenal insufficiency following adjuvant pembrolizumab therapy for renal cell carcinoma"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2963-7259","authenticated-orcid":false,"given":"Naseem","family":"Eisa","sequence":"first","affiliation":[{"name":"Endocrinology, Community Health Partners, Fresno, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"2026041407551578000_19.4.e271276.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2026041407551578000_19.4.e271276.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2026041407551578000_19.4.e271276.3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0319-9"},{"key":"2026041407551578000_19.4.e271276.4","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-7006","article-title":"Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study","volume":"10","author":"Cui","year":"2022","journal-title":"Ann Transl Med"},{"key":"2026041407551578000_19.4.e271276.5","article-title":"Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment","volume":"15","author":"Zilberman","year":"2023","journal-title":"Cureus"},{"key":"2026041407551578000_19.4.e271276.6","first-page":"1458","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases","volume":"2019","author":"Lupi","year":"2019","journal-title":"Endocr Connect"},{"key":"2026041407551578000_19.4.e271276.7","doi-asserted-by":"crossref","first-page":"1400841","DOI":"10.3389\/fendo.2024.1400841","article-title":"Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis","volume":"15","author":"van der Leij","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026041407551578000_19.4.e271276.8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026041407551578000_19.4.e271276.9","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab022","article-title":"New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays","volume":"5","author":"Javorsky","year":"2021","journal-title":"J Endocr Soc"},{"key":"2026041407551578000_19.4.e271276.10","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1530\/EJE-09-0247","article-title":"The value of IGF1 estimation in adults with GH deficiency","volume":"161 Suppl 1","author":"Mukherjee","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2026041407551578000_19.4.e271276.11","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2021-207895"},{"key":"2026041407551578000_19.4.e271276.12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1159\/000519597","article-title":"Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series","volume":"14","author":"Sonehara","year":"2021","journal-title":"Case Rep Oncol"},{"key":"2026041407551578000_19.4.e271276.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026041407551578000_19.4.e271276.14","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jtho.2017.10.023","article-title":"Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab","volume":"13","author":"Boudjemaa","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2026041407551578000_19.4.e271276.15","article-title":"Pembrolizumab-Induced Hypophysitis in the Setting of Renal Cell Carcinoma","volume":"17","author":"Ogbodu","year":"2025","journal-title":"Cureus"},{"key":"2026041407551578000_19.4.e271276.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-021-00854-y","article-title":"Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report","volume":"21","author":"Antoniou","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"2026041407551578000_19.4.e271276.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-019-0335-x","article-title":"Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report","volume":"19","author":"Takeno","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"2026041407551578000_19.4.e271276.18","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1093\/annonc\/mdx497","article-title":"Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab","volume":"28","author":"Otsubo","year":"2017","journal-title":"Ann Oncol"},{"key":"2026041407551578000_19.4.e271276.19","doi-asserted-by":"crossref","DOI":"10.1186\/s40780-024-00332-2","article-title":"Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report","volume":"10","author":"Fujimiya","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"2026041407551578000_19.4.e271276.20","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41598-022-05400-x","article-title":"Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study","volume":"12","author":"Takayasu","year":"2022","journal-title":"Sci Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-271276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:55:25Z","timestamp":1776178525000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-271276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,14]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bcr-2025-271276"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-271276","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}